Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer.

Lin, Bo; Lu, Bing; Hsieh, I-Yun; Liang, Zhen; Sun, Zicheng; Yi, Yang; Lv, Weiming; Zhao, Wei; Li, Jie

Lin, Bo; Lu, Bing; Hsieh, I-Yun; Liang, Zhen; Sun, Zicheng; Yi, Yang; Lv, Weiming; Zhao, Wei; Li, Jie.

Afiliación

Lin B; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Lu B; Institute of Urology of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen Luohu Hospital Group, Shenzhen, China.
Hsieh IY; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Liang Z; Department of Breast Surgery, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Sun Z; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yi Y; Key Laboratory of Stem Cells and Tissue Engineering (Sun Yat-sen University), Ministry of Education, Guangzhou, China.
Lv W; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhao W; Key Laboratory of Stem Cells and Tissue Engineering (Sun Yat-sen University), Ministry of Education, Guangzhou, China.
Li J; RNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Front Pharmacol ; 11: 632, 2020.

Article en En | MEDLINE | ID: mdl-32477122

Palabras clave

GSK-J4; KRAS-mutant; anaplastic thyroid cancer; epigenetics; synergistic action

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google